| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1966948 | Clinica Chimica Acta | 2008 | 5 Pages |
BackgroundThe association of the − 675 4G/5G polymorphism of the plasminogen activator inhibitor-1 (PAI-1) gene with cardiovascular disease in patients with type 2 diabetes (T2DM) is unknown.MethodsGenotyping was performed in 672 consecutive Caucasian patients undergoing coronary angiography for the evaluation of stable coronary artery disease (CAD). Vascular events were recorded over 4 years.ResultsIn non-diabetic subjects (n = 524), the homozygous PAI-1 4G4G genotype was significantly associated with significant coronary stenoses ≥ 50% (adjusted odds ratio (OR) OR = 1.84 [1.17–2.92]; p = 0.009); however, in T2DM patients (n = 148) no such association was observed (OR = 0.67 [0.26–1.71]; p = 0.401). An interaction term T2DM × 4G4G genotype was significant (p = 0.006), indicating a significantly stronger association of the polymorphism with CAD in non-diabetic subjects than in patients with T2DM. Also prospectively, the 4G4G genotype conferred an increased risk of vascular events in non-diabetic subjects but not in T2DM patients (hazard ratios 1.76 [1.13–2.74]; p = 0.014 and 0.68 [0.30–1.54]; p = 0.360, respectively). Again, the interaction T2DM × 4G4G genotype was significant (p = 0.018).ConclusionsPresence of T2DM significantly modulates the vascular risk conferred by the PAI-1 − 675 4G/5G polymorphism in angiographied coronary patients.
